Net Deals Web Search

Search results

1. Results From The WOW.Com Content Network

2. Why Novartis Stock Is Down Today Despite Topping Q2 ... - AOL

   www.aol.com/finance/why-novartis-stock-down...

   Novartis turned $12.5 billion worth of revenue into per-share earnings of $1.97 in Q2, topping expectations for a profit of $1.89 per share on sales of a little less than $12.4 billion. Better ...

3. Novartis raises sales growth target to 5% a year through 2027

   www.aol.com/news/novartis-lifts-sales-growth...

   FRANKFURT (Reuters) -Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business. The medium-term ...

4. Novartis lifts profit forecast for second time on Cosentyx ...

   www.aol.com/news/novartis-raises-2024-profit...

   Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure treatment Entresto and arthritis ...

5. Novartis - Wikipedia

   en.wikipedia.org/wiki/Novartis

   Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022. [ 4][ 5] Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to ...

6. Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

   www.aol.com/news/novartis-viatris-face-lawsuit...

   Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and ...

7. Novartis' Sandoz dips on debut after lower than expected ...

   www.aol.com/news/novartis-completes-sandoz...

   The debut made Sandoz the largest new entrant to the Swiss stock exchange since 2019, when another Novartis spin-off, eyecare company Alcon, was valued at about 28 billion francs.

8. Vasant Narasimhan - Wikipedia

   en.wikipedia.org/wiki/Vasant_Narasimhan

   He spent 8 years working in Novartis Vaccines, at the time a non-profit division focused on developing vaccines for children and patients around the world and served as the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17]

9. Novartis in advanced talks to buy Cytokinetics- source - AOL

   www.aol.com/news/novartis-advanced-talks-buy...

   (Reuters) -Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.